²ÝÁñÉçÇøÈë¿Ú

New Study Now Enrolling

A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children

If your infant or child is in overall good health, they may qualify for a study! 

Our research team is seeking toddlers and preschoolers for a new investigational pediatric intranasal RSV vaccine clinical trial at ²ÝÁñÉçÇøÈë¿Ú Vaccine Research Center. The RSV vaccine is administered to the nose as a nasal spray. 

This study will require 5 to 9 visits (some through optional tele-health video call) over the course of approximately 1 year.

Eligibility Requirements:

• Infants and children from ages 8 months to less than 17 months
• May or may not have had RSV in the past
• In overall good health
• Additional criteria may apply.

Qualified Enrolled Participants May Receive:

• No-cost, study-related care from ²ÝÁñÉçÇøÈë¿Ú Vaccine Research Center
• Study intranasal vaccine
• Compensation of up to $1,000 for time and travel

Health insurance is not required.

Ready to learn more or see if your child qualifies for this study?

Please fill out an .